Veracyte appoints Eliav Barr, M.D. to board of directors, effective August 9, 2022

VERACYTE, INC.

Dr. Barr appointed as Class III director with term expiring at 2025 annual meeting.
Also appointed to the Regulatory and Compliance Committee of the board.
Receives annual cash retainer of $40,000 plus $5,000 for committee service.
Initial restricted stock unit grant valued at $500,000, vesting over three years.
Enters standard indemnification agreement for non-executive directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eliav Barr, M.D.

Director

VCYT · VERACYTE, INC.

Effective: 2022-08-09
Filed: August 11, 2022, 7:59 PM ET

the Board appointed Eliav Barr, M.D., to serve as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Eliav Barr, M.D. was appointed as Director at VERACYTE, INC..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Eliav Barr, M.D., to serve as a director of the Company, effective immediately.

View on SEC.gov

VERACYTE, INC. filing history →

Source: SEC EDGAR

accession 0001384101-22-000121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.